The third edition of PeptideWorld, Pep IQ's monthly news digest. Coverage window: 19 June → 5 July 2026. This month the metabolic side of the field takes the lead — an oral GLP-1 is now shipping in the US, a once-monthly injectable is deep in Phase 3, and both now have full Pep IQ entries. Meanwhile the FDA's compounding advisory meeting is finally imminent. Scan the headlines, then expand each section for detail. Sourced where available; conditional where the evidence still is.
Headlines at a glance
-
Metabolic
The GLP-1 pill era arrives — orforglipron (Foundayo) is now shipping in the USEli Lilly's orforglipron, FDA-approved on 1 April 2026, is the first small-molecule GLP-1 pill you can take any time of day with no food or water rules. Now dispensed via LillyDirect and US pharmacies. New Pep IQ entry added — with the honest caveats: prescription-only, boxed thyroid warning, and not yet UK-approved.
-
Pipeline
MariTide moves deeper into Phase 3 — a once-monthly GLP-1 that blocks GIPAmgen's maridebart cafraglutide (AMG 133) showed up to ~20% weight loss in Phase 2 with monthly dosing, and its Phase 3 MARITIME programme added new arms through June 2026. Novel mechanism, real efficacy, no approval anywhere yet — and, being a biologic, genuinely not a grey-market peptide. New Pep IQ entry added.
-
Regulatory
The FDA compounding vote is now days away — seven peptides, 23–24 JulyThe Pharmacy Compounding Advisory Committee meets in under three weeks on BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon. Written comments closed 9 July territory; the committee only advises, and even a "yes" starts — not ends — a long rule-making road.
-
UK regulatory
UK position unchanged — approvals abroad don't cross the ChannelA US drug approval and a US compounding vote have zero direct UK effect. Orforglipron is not MHRA-approved; MariTide is investigational everywhere; the research peptides remain unlicensed and research-use only here. The only quiet shift is tighter enforcement around mis-marketed "research" supply.
The first no-restriction GLP-1 pill is now in pharmacies
The obesity field spent years defined by weekly injections. That is changing fast. Novo Nordisk's oral semaglutide reached weight-loss approval in December 2025, and on 1 April 2026 Eli Lilly's orforglipron — brand name Foundayo — followed as the first small-molecule GLP-1 pill. Because it is a non-peptide, it survives the gut like an ordinary tablet, so unlike oral semaglutide it can be taken at any time of day, with or without food or water.
It reached US pharmacies and LillyDirect through the spring, with a titration that runs from 0.8 mg up to a maximum of 17.2 mg once daily, stepped up no faster than every 30 days. Phase 3 (the ATTAIN programme) put mean weight loss around 11% at the higher doses over 72 weeks — solid, if generally below the peak figures of the strongest injectables — and a head-to-head in The Lancet had it beating oral semaglutide on both glucose and weight in type 2 diabetes.
We've added a full Pep IQ entry, and we've flagged what the marketing tends to skip: it carries a boxed warning for thyroid C-cell tumours and is contraindicated with a personal or family history of MTC or MEN-2; it is prescription-only; and it is not yet approved in the UK. A pill is also easier to counterfeit than an injectable, so an unverified "orforglipron" ahead of MHRA approval is exactly the kind of grey-market risk this site exists to name.
- Any EMA / MHRA movement — the UK/EU route is separate from the FDA and not yet complete
- Real-world tolerability and discontinuation rates now it's out of the trial setting
- Counterfeit "oral GLP-1" supply appearing ahead of UK approval
A monthly injectable that blocks GIP instead of activating it
Amgen's MariTide (maridebart cafraglutide, formerly AMG 133) is the most mechanistically interesting compound in the obesity pipeline right now. It is an antibody-peptide conjugate that activates the GLP-1 receptor while blocking the GIP receptor — the opposite GIP direction to tirzepatide, which activates it. That both approaches produce large weight loss tells you the biology of GIP in obesity is genuinely unsettled.
Its Phase 2 trial reported mean weight loss of up to about 20% in obesity without diabetes, and up to ~17% with type 2 diabetes, over 52 weeks — at once-monthly dosing, thanks to the long half-life the antibody backbone provides. Through June 2026 the Phase 3 MARITIME programme kept expanding, with arms now registered across obesity, type 2 diabetes, obstructive sleep apnoea and elevated liver fat.
The new Pep IQ entry carries one blunt point: MariTide is a biologic, not a research peptide. There is no legitimate supply outside Amgen's trials, and you cannot reproduce an antibody-drug conjugate in a peptide vial — so anything sold as "MariTide" or "AMG 133" on the grey market is almost certainly counterfeit. This is one to follow, not to source.
- Phase 3 MARITIME primary readouts — whether the ~20% Phase 2 signal holds at scale
- Long-term consequences of chronic GIP antagonism, a novel intervention in humans
- Cardiovascular outcome and tolerability data as the programme matures
The compounding vote we've tracked since Issue 01 is finally here
The FDA's Pharmacy Compounding Advisory Committee meets on 23–24 July 2026 to consider whether seven bulk substances should join the Section 503A list that authorises patient-specific compounding. Day one covers BPC-157, KPV, TB-500 and MOTS-c; day two covers DSIP, Semax and Epitalon — almost the entire repair, cognitive and longevity spine of this site.
Two cautions we keep repeating, because the louder coverage keeps dropping them. These peptides had been parked in the safety-concern category, and a prior review cycle voted against inclusion — a friendlier political climate does not guarantee a different scientific vote. And the committee only advises: even a favourable vote starts, rather than ends, a multi-stage rule-making process before any pharmacy can act on it. A milestone, not a finish line.
- The FDA's background review materials, posted roughly two business days before 23 July — the clearest signal of each vote's direction
- The committee's day-by-day recommendation on all seven
- How quickly, if at all, a positive vote turns into an actual rule
None of the above changes anything for a UK reader
It's worth stating plainly every month: US approvals and US compounding votes have no direct UK effect. Orforglipron is FDA-approved but has no MHRA marketing authorisation — it is not a licensed UK medicine. MariTide is investigational everywhere. And the research peptides on this site remain unlicensed and research-use only in the UK, whatever the FDA decides on 23–24 July.
The only quiet movement is on enforcement: continued friction around mis-marketed "research use only" supply and the payment processors that serve it. As always, for anything sold as a research compound, the certificate of analysis matters more than the headline — and "legal to possess" is never the same as safe, approved, or recommended.
- Approved abroad ≠ approved here — check MHRA status before assuming a UK route exists
- For the metabolic drugs, the supervised, prescribed route is the one with the safety record
- For everything else, unlicensed and research-use only — sourcing risk sits with the buyer